tetano
Editor, Senior Moderator
J Med Virol
. 2024 Mar;96(3):e29541.
doi: 10.1002/jmv.29541. Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19
Samantha C Roberts[SUP] 1 [/SUP], Sarah E Jolley[SUP] 2 [/SUP], Laurel E Beaty[SUP] 1 [/SUP], Neil R Aggarwal[SUP] 2 [/SUP], Tellen D Bennett[SUP] 3 4 [/SUP], Nichole E Carlson[SUP] 1 5 [/SUP], Lindsey E Fish[SUP] 6 [/SUP], Bethany M Kwan[SUP] 7 [/SUP], Seth Russell[SUP] 3 [/SUP], Adane F Wogu[SUP] 1 [/SUP], Matthew A Wynia[SUP] 8 9 [/SUP], Adit A Ginde[SUP] 10 [/SUP]
Affiliations
Effective therapies for reducing post-acute sequelae of COVID-19 (PASC) symptoms are lacking. Evaluate the association between monoclonal antibody (mAb) treatment or COVID-19 vaccination with symptom recovery in COVID-19 participants. The longitudinal survey-based cohort study was conducted from April 2021 to January 2022 across a multihospital Colorado health system. Adults ≥18 years with a positive SARS-CoV-2 test were included. Primary exposures were mAb treatment and COVID-19 vaccination. The primary outcome was time to symptom resolution after SARS-CoV-2 positive test date. The secondary outcome was hospitalization within 28 days of a positive SARS-CoV-2 test. Analysis included 1612 participants, 539 mAb treated, and 486 with ≥2 vaccinations. Time to symptom resolution was similar between mAb treated versus untreated patients (adjusted hazard ratio (aHR): 0.90, 95% CI: 0.77-1.04). Time to symptom resolution was shorter for patients who received ≥2 vaccinations compared to those unvaccinated (aHR: 1.56, 95% CI: 1.31-1.88). 28-day hospitalization risk was lower for patients receiving mAb therapy (adjusted odds ratio [aOR]: 0.31, 95% CI: 0.19-0.50) and ≥2 vaccinations (aOR: 0.33, 95% CI: 0.20-0.55), compared with untreated or unvaccinated status. Analysis included 1612 participants, 539 mAb treated, and 486 with ≥2 vaccinations. Time to symptom resolution was similar between mAb treated versus untreated patients (adjusted hazard ratio (aHR): 0.90, 95% CI: 0.77-1.04). Time to symptom resolution was shorter for patients who received ≥2 vaccinations compared to those unvaccinated (aHR: 1.56, 95% CI: 1.31-1.88). 28-day hospitalization risk was lower for patients receiving mAb therapy (adjusted odds ratio [aOR]: 0.31, 95% CI: 0.19-0.50) and ≥2 vaccinations (aOR: 0.33, 95% CI: 0.20-0.55), compared with untreated or unvaccinated status. COVID-19 vaccination, but not mAb therapy, was associated with a shorter time to symptom resolution. Both were associated with lower 28-day hospitalization.
Keywords: COVID‐19; monoclonal antibody therapy; post‐acute sequelae of COVID‐19; vaccination.
. 2024 Mar;96(3):e29541.
doi: 10.1002/jmv.29541. Association between monoclonal antibody therapy, vaccination, and longer-term symptom resolution after acute COVID-19
Samantha C Roberts[SUP] 1 [/SUP], Sarah E Jolley[SUP] 2 [/SUP], Laurel E Beaty[SUP] 1 [/SUP], Neil R Aggarwal[SUP] 2 [/SUP], Tellen D Bennett[SUP] 3 4 [/SUP], Nichole E Carlson[SUP] 1 5 [/SUP], Lindsey E Fish[SUP] 6 [/SUP], Bethany M Kwan[SUP] 7 [/SUP], Seth Russell[SUP] 3 [/SUP], Adane F Wogu[SUP] 1 [/SUP], Matthew A Wynia[SUP] 8 9 [/SUP], Adit A Ginde[SUP] 10 [/SUP]
Affiliations
- PMID: 38516779
- DOI: 10.1002/jmv.29541
Effective therapies for reducing post-acute sequelae of COVID-19 (PASC) symptoms are lacking. Evaluate the association between monoclonal antibody (mAb) treatment or COVID-19 vaccination with symptom recovery in COVID-19 participants. The longitudinal survey-based cohort study was conducted from April 2021 to January 2022 across a multihospital Colorado health system. Adults ≥18 years with a positive SARS-CoV-2 test were included. Primary exposures were mAb treatment and COVID-19 vaccination. The primary outcome was time to symptom resolution after SARS-CoV-2 positive test date. The secondary outcome was hospitalization within 28 days of a positive SARS-CoV-2 test. Analysis included 1612 participants, 539 mAb treated, and 486 with ≥2 vaccinations. Time to symptom resolution was similar between mAb treated versus untreated patients (adjusted hazard ratio (aHR): 0.90, 95% CI: 0.77-1.04). Time to symptom resolution was shorter for patients who received ≥2 vaccinations compared to those unvaccinated (aHR: 1.56, 95% CI: 1.31-1.88). 28-day hospitalization risk was lower for patients receiving mAb therapy (adjusted odds ratio [aOR]: 0.31, 95% CI: 0.19-0.50) and ≥2 vaccinations (aOR: 0.33, 95% CI: 0.20-0.55), compared with untreated or unvaccinated status. Analysis included 1612 participants, 539 mAb treated, and 486 with ≥2 vaccinations. Time to symptom resolution was similar between mAb treated versus untreated patients (adjusted hazard ratio (aHR): 0.90, 95% CI: 0.77-1.04). Time to symptom resolution was shorter for patients who received ≥2 vaccinations compared to those unvaccinated (aHR: 1.56, 95% CI: 1.31-1.88). 28-day hospitalization risk was lower for patients receiving mAb therapy (adjusted odds ratio [aOR]: 0.31, 95% CI: 0.19-0.50) and ≥2 vaccinations (aOR: 0.33, 95% CI: 0.20-0.55), compared with untreated or unvaccinated status. COVID-19 vaccination, but not mAb therapy, was associated with a shorter time to symptom resolution. Both were associated with lower 28-day hospitalization.
Keywords: COVID‐19; monoclonal antibody therapy; post‐acute sequelae of COVID‐19; vaccination.